Renal-cell carcinoma (RCC) incidence and mortality have been changing for many reasons. We used the Surveillance, Epidemiology, and End Results database to review 104,584 RCC cases with 47,561 deaths diagnosed between 1992 and 2015. Despite an overall increase in the incidence of RCC, there has been a recent plateau in RCC incidence rates with a significant decrease in mortality. Background: Renal-cell carcinoma (RCC) is one of the common malignancies in the United States. RCC incidence and mortality have been changing for many reasons. We performed a thorough investigation of incidence and mortality trends of RCC in the United States using the cell Surveillance, Epidemiology, and End Results (SEER) database. Patients and Methods: The 13 SEER registries were accessed for RCC cases diagnosed between 1992 and 2015. Incidence and mortality were calculated by demographic and tumor characteristics. We calculated annual percentage changes of these rates. Rates were expressed as 100,000 person-years. Results: A total of 104,584 RCC cases were reviewed, with 47,561 deaths. The overall incidence was 11.281 per 100,000 person-years. Incidence increased by 2.421% per year (95% confidence interval, 2.096, 2.747; P < .001) but later became stable since 2008. However, the incidence of clear-cell subtype continued to increase (1.449%; 95% confidence interval, 0.216, 2.697; P ¼ .024). RCC overall mortality rates have been declining since 2001. However, mortality associated with distant RCC only started to decrease in 2012, with an annual percentage change of 18.270% (95% confidence interval, À28.775, À6.215; P ¼ .006). Conclusion: Despite an overall increase in the incidence of RCC, there has been a recent plateau in RCC incidence rates with a significant decrease in mortality.
Introduction
Renal-cell carcinoma (RCC) is ranked as the sixth and tenth most common malignancy in American male and female subjects, respectively. 1 In the United States, the estimated number of diagnosed cases in 2018 is 65,340 and the estimated number of deaths is 14,970. 2 Histologically, RCC is further classified into subtypes; the most common is clear-cell histology, followed by papillary subtype. 1 An increase in incidence may be attributed to incidental diagnosis due to increased use of ultrasound and computed tomography (CT) in health care settings, as well as shifts in the prevalence of RCC risk factors such as smoking, obesity, and hypertension. 3, 4 A delicate interplay between the decline in consumption of tobacco products in industrialized countries and an increased prevalence of obesity and hypertension may influence RCC incidence. A continuous analysis of epidemiologic data is crucial in understanding the incidence and mortality trends in different populations. In this study, we used the Surveillance, Epidemiology, and End Results (SEER) cancer registry to study the trends in the incidence and mortality of RCC in the United States over the past 20 years.
Methods

Data Source
We used SEER*stat 8.3.5 software to access the SEER database. We used the 13 SEER registries (November 2017 submission), which includes data of patients from 1992 to 2015, and covers about 13.4% of the US population.
10,11
Study Population
We included RCC cases diagnosed between 1992 and 2015, the diagnosis of which did not rely only on autopsy or death certificates. For this selection, we used the following SEER variables: "primary site-labeled: C64.9-Kidney, NOS," and "Histology recodebroad groupings: 8140-8389 adenomas and adenocarcinomas." We reviewed the following variables within the selected cases: sex, race, age at diagnosis (or age at death in case of mortality calculation), state, stage at diagnosis (using SEER histologic stage A), tumor size, and histologic subtype (using ICD-O-3 histology recode). In addition, we performed a subgroup analysis for clear-cell RCC cases separately and reviewed the same mentioned variables in this population.
Outcomes
We calculated incidence and incidence-based mortality rates for the RCC population and clear-cell population according to the previously mentioned variables. Rates were adjusted to the 2000 US standard population and expressed as 100,000 person-years. Incidence-based mortality was calculated as the number of RCC deaths among cases diagnosed over person-time at risk among people in SEER areas. 12 Rates were calculated during 1992-2015 except for chromophobe RCC cases (1992-2015 for incidence and 1997-2015 for mortality) and collecting duct RCC cases (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) . To observe the change of rates over the study period, we calculated the annual percentage changes (APCs).
Statistical Analysis
Incidence and incidence-based mortality rates were calculated by SEER*stat software. 11 APCs were calculated using the National Cancer Institute's Joinpoint regression program, version 4.5.0.1.
13
The software examined rates over time and detected significant changes in APCs, then selected the best model with the least number of join points.
14 P values were calculated by t tests and were considered significant when less than .05. All statistical tests were 2 sided.
Results
Baseline Characteristics
We reviewed data of 104,584 patients with RCC diagnosed during 1992-2015 ( 
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those patients were male (65%), white (81.6%), and older than 65 (71.4%).
Incidence Rates and Trends Over Time
The overall RCC incidence during the study period was 11.281 per 100,000 person-years (95% confidence interval [ Tables 1 and 2 in the online version).
Over the study period, RCC incidence rates increased at 2.421% per year (95% CI, 2.096, 2.747; P < .001). However, this increase in incidence plateaued over the last 7 years of the study period (2008-2015) (APC of 0.111%; 95% CI, À0.483, 0.708; P ¼ .699). Furthermore, this overall increase was reflected over most of the various study subgroups, including white subjects (APC of 2.444; 95% CI, 2.107, 2.783; P < .001) and black subjects (APC of 2.579; 95% CI, 2.069, 3.091; P < .001). This incremental incidence in RCC, however, was mostly notable in the localized and regional diseases rather than distant RCC, where the overall incidence was stable (APC of À0.240%; 95% CI, À0.551, 0.072; P ¼ .125) ( Figure 1 , Table 2 , Supplemental Table 3 in the online version).
Incidence-Based Mortality Rates and Trends Over Time
Overall incidence-based mortality rates of RCC during the study period was 5.256 (95% CI, 5.209, 5.304) per 100,000 personyears. Incidence-based mortality rates were highest among male subjects (8. Tables 1 and 2 in the online version).
Over the study period, RCC incidence-based mortality rates decreased by À2.159% per year (95% CI, À3.342, À0.962; P < .001). The incidence-based mortality rates increased from 1992 and peaked in 2001, when it started to decrease significantly until 2015. This recent decrease in mortality became more pronounced since 2013 (APC of À32.242; 95% CI, À38.991, À24.745; P < .001). This trend was noted in most subgroups, including male subjects (APC of À2.110; 95% CI, À3.322, À0.883; P < .001), female subjects (APC of À2.725; 95% CI, À4.099, À1.331; P < .001), white subjects (APC of À2.505; 95% CI, À3.691, À1.304; P < .001), and black subjects (APC of À1.738; 95% CI, À3.205, À0.250; P < .001) ( Figure 2 , Table 3, Supplemental Table 4 in the online version).
Discussion
Our study evaluated the trends of incidence and mortality rates of RCC in the United States by using a single comprehensive registry system (SEER database) over 2 decades. We found that there had been an initial overall increase in incidence and mortality rates of RCC. However, over the last decade, there has been a plateau in the incidence of RCC, accompanied by a significant improvement in mortality.
The changes in the incidence rate may be attributed to incidental diagnosis and/or changes in the prevalence of RCC risk factors. Recently there has been a significant increase in the use of advanced abdominal imaging in the evaluation of unrelated abdominal symptoms. 15, 16 For example, a recent study found that the frequent use of CT scans is associated with increased risk of undergoing a nephrectomy. 17 CT scans have a better sensitivity in detecting a renal mass than an ultrasound. However, imaging studies cannot reliably distinguish benign versus malignant features of solid renal masses, prompting more intensive workup for all solid tumors, regardless of size. [18] [19] [20] [21] In addition to an increase in the use of abdominal imaging, the prevalence of the risk factors affecting RCC has been shifting over the years. Changing prevalence of environmental factors affecting RCC constitutes a real change in incidence, rather than a mere increase in detection. Several environmental factors have been implied as risk factors for RCC, such as smoking, occupational exposure to cadmium and asbestos, phenacetin-containing analgesics, and chemotherapeutic agents used for childhood malignancies. In addition to chemical exposure, numerous medical conditions can increase the risk of RCC, namely obesity, hypertension, diabetes mellitus, and dialysis. [22] [23] [24] [25] [26] Smoking increases the risk of RCC as well as the risk of lymph node involvement and distant metastasis at presentation. This increased risk is evident in both current and previous smokers. 5, 27, 28 However, smoking has been trending down in the United States over the past 5 decades, which significantly correlates with the RCC trends. 28 In contrast to the decreasing prevalence of smoking in the United States, the prevalence of medical conditions that increase the risk of RCC has been on the rise over the past decades. Since 1960, the prevalence of obesity has increased 3-fold, and diabetes mellitus has increased 7-fold. [29] [30] [31] Obesity is associated with a higher risk of developing RCC. Paradoxically, it is also associated with lower stage at diagnosis as well as longer survival. 32, 33 Those changes in lifestyle factors in the United
States-declining smoking and increased obesity and diabeteshave significantly affected incidence rates and mortality of the developed RCC. Management of patients with RCC is multidisciplinary, consisting of surgical resection, radiotherapy, and systemic therapy. For a patient with limited, localized disease, surgical resection is the treatment of choice, which can be either radical or partial nephrectomy. Partial nephrectomy can be done laparoscopically, is less invasive, and can be used to resect multiple smaller tumors while preserving renal parenchymal tissue that is used in patients who have impaired renal function, bilateral disease, or a single kidney. 34 Radical nephrectomy is more commonly used and is more appropriate for lesions with regional invasion. 35 Several studies have assessed the survival of patient undergoing partial versus radical nephrectomy and have found that partial nephrectomy is associated with a better overall and cancerspecific survival. However, populations with the specific cancer stages of T1b and T2 were the populations that had better survival outcomes after partial nephrectomy.
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The introduction of vascular endothelial growth factor (VEGF) inhibitors (also known as antiangiogenics) and checkpoint inhibitors for advanced cases of RCC has significantly affected the survival of these patients. [39] [40] [41] [42] The US Food and Drug Administration approval of sorafenib and sunitinib in 2005 and 2006, respectively, followed by the approval of more antiangiogenic therapies, were pivotal points in the treatment of advanced RCC. After the approval of the first VEGF inhibitors, mammalian target of rapamycin (mTOR) inhibitors were also developed and were used as monotherapies or in combination in the treatment of advanced clear-cell RCC. The activity of the newer targeted therapies has been investigated over the last decade by many clinical trials, which concluded that the VEGF tyrosine kinase inhibitors and mTOR inhibitors were associated with improved overall and progressive disease survival. 43 The decreasing mortality trends seen starting 2007 and continuing until 2015 are associated with the introduction of such therapies for RCC treatment. 44 In addition, mortality rates of cases of distant metastasis have decreased significantly during that time period. This further solidifies the evidence that the introduction of VEGF inhibitors for patients with RCC has significantly affected the survival and mortality. Other studies have also reported trends similar to our results, noting a decline in mortality after introduction of VEGF inhibitors. 45, 46 This study has certain limitations. We did not perform mortality over incidence analysis. While the mortality over incidence analysis could account for the variation in incidence over time, a recent study demonstrated a correlation between changes in survival rates and mortality over incidence changes over time, showing that survival measures alone can be used as a rough estimation of progress in clinical care of cancer. 47 Sources of bias and variations exist as a result of the retrospective and descriptive nature of our study. In addition, the SEER database does not capture environmental exposure or individual lifestyle habits and comorbidities, thus negating the documentation of a direct association between individual exposure and the incidence and mortality of RCC, thus only allowing speculation over the association among the observed trends. In addition, the SEER database was limited in tumor histology, with a large number of cases described as being of unknown histology. Moreover, data on tumor size and stage were only available for certain years, thus leading to a potential bias in data analysis and results. In addition, the SEER database does not contain clinically important data or information about temporal follow-up of patients. 48 Although the SEER database is not sensitive enough to compare outcomes conditioned on treatment or comparative effectiveness research, it certainly covers approximately 10% to 30% of the US population based on the registry. On top of that, the SEER database is one of the best epidemiologic tools and databases currently available to study incidence and mortality trends.
Conclusion
In patients residing in the United States with a diagnosis of RCC during 1992-2015, overall incidence and mortality rates have increased. However, recent years have shown that the incidence rates have stabilized and the mortality rates have decreased. The changes seen in the incidence trends may be attributed to increasing detection in addition to social changes in the prevalence of Table 3 Continued 
Anas M. Saad et al
Clinical Genitourinary Cancer February 2019 -55 modifiable risk factors. The decreasing mortality trends can be correlated to multiple factors, including the improvement in overall survival and the management of advanced disease with the introduction of antiangiogenics and the impact that these therapeutic agents have had on RCC survival.
Clinical Practice Points
RCC incidence and mortality have been changing for many reasons. Since the 1990s, the mortality rates of RCC have been declining in Western countries. A continuous analysis of epidemiologic data is crucial to understand the incidence and mortality trends in different populations. We used SEER to review 104,584 RCC cases with 47,561 deaths diagnosed between 1992 and 2015. In patients residing in the United States with a diagnosis of RCC from 1992 to 2015, overall incidence and mortality rates have increased. However, recent years have shown that the incidence rates have stabilized and the mortality rates have decreased. The decreasing mortality may be correlated to the improvement in overall survival and the management of advanced disease with the introduction of antiangiogenic therapy.
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